Product
KAND567
3 clinical trials
5 indications
Indication
HealthyIndication
COVID-19Indication
Ovarian CancerIndication
Fallopian tube cancerIndication
Peritoneal CancerClinical trial
Safety, Tolerability and Pharmacokinetics After Continuous Infusion of KAND567. A Single-centre, Placebo-controlled, Randomised, Double-blind Study in Healthy SubjectsStatus: Completed, Estimated PCD: 2020-04-27
Clinical trial
KAND567 Versus Placebo in Subjects Hospitalized With COVID-19. A Phase II, Randomized, 2-Arm Parallel-Group, Double-blind Study to Evaluate Efficacy, Safety, Tolerability, and PharmacokineticsStatus: Terminated, Estimated PCD: 2021-08-07
Clinical trial
KANDOVA - A Two-Part Phase Ib/IIa Study to Evaluate the Safety and Tolerability of KAND567, in Combination With Carboplatin Therapy, and to Determine the Recommended Phase II Dose (RPIID) of KAND567: An Open-Label, Multicenter Dose Escalation Study With an Expansion Cohort in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerStatus: Recruiting, Estimated PCD: 2024-06-30